In clinical studies, high plasma VEGF-D differentiated PH-LHD from PAH, chronic thromboembolic PH (CTEPH) and controls, and a similar increase was related to PAH progression in systemic sclerosis patients [13, 14]. The gene discussed is VEGFD; the disease is systemic sclerosis.